Accelerating Breakthrough Discoveries into Medicines

Ann Marie Schmidt, MD

Dr. Schmidt is targeting RAGE/mDia1 for the prevention and treatment of diabetic complications.

Ann Marie Schmidt, MD is the director of the Diabetes Research Program at New York University Langone Medical Center in New York and the first Dr. Iven Young Professor of Endocrinology at NYU. She is a Professor of Medicine, Pharmacology and Pathology.

Dr. Schmidt is acutely aware that the epidemic of diabetes causes significant morbidity and mortality in affected subjects and escalates health care costs. Current therapies do not prevent diabetic complications; they intervene in later disease stages, when the tissue damage cannot be reversed. Diabetes is a leading cause of blindness and amputations and therefore its therapeutic targeting is essential for human health. Dr. Schmidt and her team are working to fill a critical gap in diabetes by identifying disease-modifying agents for diabetic retinopathy and wound healing, which may be locally administered.

The Schmidt lab has discovered the mechanisms by which a key molecule implicated in diabetic complications, known as the receptor for advanced glycation endproducts (RAGE), acts inside cells to alter cellular properties and contribute to the pathogenesis of diabetic complications. Through a high throughput screening assay, they have identified two distinct lead series (LS) of small molecules that block the intracellular actions of this molecule; these compounds are novel and demonstrate activity and early safety and stability.

Dr. Schmidt has assembled a team of scientists to develop therapies for diabetic retinopathy and wound healing, including experts in medicinal and computational chemistry, the biology of RAGE, and in local intravitreal and dermal therapies for these conditions.

Successful completion of their studies will identify compounds ready for pre-IND candidate selection studies followed by subsequent IND-enabling safety studies for ophthalmic and dermal complications of diabetes.

Dr. Schimidt earned her B.A. in biology and history summa cum laude from NYU’s Washington Square College and her M.D. degree with honors from NYU School of Medicine. She remained at NYU to complete her medical residency and chief residency, as well as a fellowship in hematology and medical oncology. She then moved to Columbia University, joining the department of physiology and cellular biophysics as a Post-doctoral Fellow of the Juvenile Diabetes Research Foundation (JDRF). From 2003 to 2010, she served as the Chief of the Division of Surgical Science and the Gerald and Janet Carrus Professor of Surgical Science at Columbia University before returning to her alma mater.

Dates to Know

April 5, 2017
Letter of Intent Deadline

May 31, 2017
Full Application Deadline (For those invited)

December 2017
Awardees Notified

Harrington Project

The Harrington Discovery Institute is the nonprofit arm of the Harrington Project for Discovery & Development, an international initiative supporting breakthrough research by physician-scientists. The Project is a new and powerful approach to address some of the challenges hindering advancement of medicine today.

The Harrington Grant is an important part of the overall pharmaceutical research initiative created by The Harrington Project.

For Questions

For questions about the Scholar-Innovator grants or the application process, please email